Amphastar Pharmaceuticals (AMPH) Fundamentals 2026 — P/E 11.3x, Revenue Analysis | SniperIQ

9.32 on the NASDAQ. This SniperIQ fundamentals page covers Amphastar Pharmaceuticals's valuation (P/E 11.3x, P/B 1.1x), profitability (net margin 11.0%), revenue ($720M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Amphastar Pharmaceuticals's market cap?

Amphastar Pharmaceuticals (AMPH) has a market capitalization of approximately $852M, trading at

9.32 on the NASDAQ. Market cap moves with the live share price.

What is Amphastar Pharmaceuticals's P/E ratio?

Amphastar Pharmaceuticals's trailing twelve-month P/E ratio is 11.3x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals runs a net profit margin of 11.0%, a gross margin of 47.3%, and an operating margin of 16.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Amphastar Pharmaceuticals generate?

Amphastar Pharmaceuticals reported revenue of $720M for fiscal year 2025, with net income of $98M and earnings per share (EPS) of 2.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Amphastar Pharmaceuticals pay a dividend?

Amphastar Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Amphastar Pharmaceuticals financially healthy?

Amphastar Pharmaceuticals carries a debt-to-equity ratio of 0.89x and a current ratio of 3.85x, with a market beta of 0.89. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Amphastar Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Amphastar Pharmaceuticals (AMPH) the key facts are: market cap $852M, P/E 11.3x, revenue $720M, 52-week range 16.65-31.26. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.